Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q3 2026 › vs Q2 2026
Ginkgo Bioworks Holdings (DNA) Q3 2026 vs Q2 2026 (quarter over quarter)
Ginkgo Bioworks Holdings's revenue rose $7.6M (+37%) from $20.2M in Q2 2026 to $27.7M in Q3 2026.
Ginkgo Bioworks Holdings, Q3 2026: revenue $27.7M (-6% year over year), operating margin -157.5%, net loss $41.0M, operating cash flow −$28.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $27.7M | $20.2M | $7.6M | +37% |
| Other income, net | $2.4M | $12.0M | −$9.6M | -80% |
| Income tax benefit | $271K | −$128K | $399K | — |
| Net loss | $41.0M | $46.7M | −$5.7M | -12% |
| Costs & expenses | $71.3M | $78.8M | −$7.5M | -9% |
| Operating costs | $71.3M | $78.7M | −$7.4M | -9% |
| Cost of revenue | $1.8M | $1.7M | $87K | +5% |
| Research & development | $40.9M | $46.2M | −$5.3M | -11% |
| General & admin | $28.6M | $30.8M | −$2.2M | -7% |
| Operating cash sources | $48.1M | $64.2M | −$16.1M | -25% |
| Depreciation & amortization | $12.0M | $12.3M | −$277K | -2% |
| Share-based compensation | $7.7M | $7.6M | $74K | +1% |
| Cash used in operations | $28.3M | $44.3M | −$15.9M | -36% |
| Net loss absorbed | $41.0M | $46.7M | −$5.7M | -12% |
| Working capital & other | $7.1M | $17.5M | −$10.4M | -60% |
Questions
How much did Ginkgo Bioworks Holdings's revenue grow quarter over quarter in Q3 2026?
Ginkgo Bioworks Holdings's revenue rose $7.6M (+37%) from $20.2M in Q2 2026 to $27.7M in Q3 2026.